| Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript |
Altimmune, Inc. (NASDAQ:ALT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Greg Weaver - Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Annabel Samimy - Stifel Liisa Bayko - Evercore William Wood - B. Riley Securities Jonathan Wolleben - Citizens JMP Patrick Trucchio - H.C. |
seekingalpha.com |
2025-02-27 16:24:55 |
Czytaj oryginał (ang.) |
| Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update |
Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to Company Board of Directors Cash, cash equivalents and short-term investments of $131.9 million on December 31, 2024 Webcast to be held today, February 27, 2025, at 8:30 a.m. |
globenewswire.com |
2025-02-27 09:00:00 |
Czytaj oryginał (ang.) |
| ALT5 Sigma Wins Best Payment Provider Award at SiGMA Eurasia 2025 |
ALT5 Sigma honored for delivering enterprise-grade crypto payment solutions that enhance security, compliance, and transaction efficiency LAS VEGAS, NEVADA / ACCESS Newswire / February 26, 2025 / ALT5 Sigma Corporation (Nasdaq:ALTS), a leading fintech innovator specializing in blockchain-powered trading and payment solutions, is proud to announce that it has been named Best Payment Provider at the SiGMA Eurasia Awards 2025. This award recognizes ALT5 Sigma's leadership in digital asset payments, honoring its secure, efficient, and scalable solutions that enable businesses to transact effortlessly with cryptocurrency. |
accessnewswire.com |
2025-02-26 16:00:00 |
Czytaj oryginał (ang.) |
| Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors |
Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career |
globenewswire.com |
2025-02-25 09:30:00 |
Czytaj oryginał (ang.) |
| Old Glory Bank and ALT 5 Sigma Expand Crypto Payment Options for Reg A+ Offering |
Now Accepting $TRUMP Coin, Along with Bitcoin, Ethereum, Bitcoin Cash, Dogecoin, Litecoin, and More LAS VEGAS, NV / ACCESS Newswire / February 20, 2025 / Old Glory Bank, a pro-America financial institution, and ALT5 Sigma Corporation ("ALT5") (Nasdaq:ALTS), a leading fintech innovator specializing in blockchain-powered solutions, today announced the expansion of crypto payment options for investors in Old Glory Bank's Regulation A+ (Reg A+) mini-IPO . Along with Bitcoin, Ethereum, Bitcoin Cash, Dogecoin, Litecoin, and other cryptocurrencies, the $TRUMP Coin can now be accepted as a payment method for subscribing to Old Glory Bank's mini-IPO. |
accessnewswire.com |
2025-02-20 10:30:00 |
Czytaj oryginał (ang.) |
| Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 |
GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. |
globenewswire.com |
2025-02-20 09:30:00 |
Czytaj oryginał (ang.) |
| ALT5 Sigma Adds the Official $TRUMP Coin to Its Trading and Payment Platforms |
ALT5 Pay Merchants can now accept $TRUMP for payments, with seamless USD or stablecoin conversion. LAS VEGAS, NV / ACCESS Newswire / February 18, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a leading fintech innovator specializing in blockchain-powered solutions, today announced that the Official $TRUMP Coin has been added to both its ALT5 Prime trading platform and to ALT5 Pay, a cutting-edge cryptocurrency payment platform designed for global merchants. |
accessnewswire.com |
2025-02-18 10:30:00 |
Czytaj oryginał (ang.) |
| Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH |
Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH (metabolic dysfunction-associated steatohepatitis). Pemvidutide has successfully completed a Phase 1 trial for a related liver disease but has yet to demonstrate efficacy in the target indication of MASH. |
seekingalpha.com |
2025-02-18 07:26:07 |
Czytaj oryginał (ang.) |
| ALT5 Nominated for SiGMA Best Online Payment Services 2025, Exhibiting at SiGMA Eurasia in Dubai, February 23-25 |
LAS VEGAS, NEVADA / ACCESS Newswire / February 13, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a leading fintech company specializing in next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and the safekeeping of digital assets, is proud to announce its nomination for the SiGMABest Online Payment Services 2025 award. This recognition coincides with ALT5 Sigma's participation in SiGMA Eurasia, one of the world's premier fintech and blockchain conferences, set to take place in Dubai on February 23-25, 2025. |
accessnewswire.com |
2025-02-13 17:00:00 |
Czytaj oryginał (ang.) |
| ALT5 Sigma Partners With Odoo to Offer Crypto Payments Capabilities Through Odoo Marketplace |
-Odoo is the most installed business software in the world, used by over 13,000,000 users worldwide ranging from startup companies (1 user) to large enterprises (300,000+ users)- LAS VEGAS, NV / ACCESS Newswire / February 3, 2025 / ALT5 Sigma Corporation (Nasdaq:ALTS), a leading fintech innovator specializing in blockchain-powered technologies, is pleased to announce a partnership with Odoo, a globally recognized provider of fully integrated business applications. This collaboration will integrate ALT5 Pay into Odoo's suite of POS, eCommerce, and ERP systems, empowering Odoo's 13 million users across 170 countries with seamless cryptocurrency payment solutions. |
accessnewswire.com |
2025-02-03 09:30:00 |
Czytaj oryginał (ang.) |
| Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference |
GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows: |
globenewswire.com |
2025-01-29 09:30:00 |
Czytaj oryginał (ang.) |
| ALT5 Sigma Corporation Partners With Hashtag Influencer to Enable Cryptocurrency Payment Processing for Influencer Marketing |
LAS VEGAS, NV / ACCESSWIRE / January 15, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a prominent innovator in the cryptocurrency sector, is pleased to announce a partnership with Hashtag Influencer, an advanced AI-powered SocialFi platform. This collaboration aims to enhance the influencer marketing landscape by enabling influencers in the gig economy to seamlessly and compliantly accept cryptocurrency payments for advertising deals with brands through social media platforms such as Instagram, Facebook, YouTube, and LinkedIn. |
accesswire.com |
2025-01-15 09:00:00 |
Czytaj oryginał (ang.) |
| ALT5 Sigma to Exhibit at iFX EXPO Dubai January 14-16, 2025 |
LAS VEGAS, NEVADA / ACCESSWIRE / January 9, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced its participation in the upcoming iFX EXPO Dubai. ALT5 will be exhibiting through the three days of the show at the Dubai World Trade Centre, providing product demonstrations, solutions and general information to many of the 7,000+ attendees starting January 14th in booth #26. |
accesswire.com |
2025-01-09 13:30:00 |
Czytaj oryginał (ang.) |
| Altimmune Could Find A Partner For Its Phase 3 Exercise |
ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while at the current rate, but not to fund phase 3, the company needs a partner or a buyout. If ALT can't find a partner or be acquired, then a hefty fund raise awaits investors, which could hit the stock. |
seekingalpha.com |
2024-12-30 13:42:43 |
Czytaj oryginał (ang.) |
| Why Altimmune Was Such a Robustly Healthy Stock on Thursday |
Altimmune (ALT 3.54%) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized stock index; investors greeted this news by trading the company's stock up by more than 3% on the day. |
fool.com |
2024-12-19 20:35:00 |
Czytaj oryginał (ang.) |
| Altimmune Added to Nasdaq Biotechnology Index |
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024. |
globenewswire.com |
2024-12-19 09:30:00 |
Czytaj oryginał (ang.) |
| ALT5 Sigma Announces Results of 2024 AGM and Corporate Update |
All resolutions were approved LAS VEGAS, NV / ACCESSWIRE / December 18, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a leading fintech firm offering next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safekeeping of digital assets, today announced that all proposed binding resolutions were approved at its 2024 Annual General Meeting (AGM). Shareholders re-elected Ron Pitters, Richard D. |
accesswire.com |
2024-12-18 18:00:00 |
Czytaj oryginał (ang.) |
| Altimmune 2025: Redefining Obesity And MASH Treatment |
Altimmune is entering both obesity and MASH markets with a powerful GLP-1/Glucagon dual-agonist drug called Pemvidutide, offering fat-specific weight loss and muscle preservation with a strong safety profile. Altimmune is redefining success in both obesity and MASH to position Pemvidutide in "blue ocean" categories not addressed by incumbents and catered to the unique strengths of Glucagon in Pemvidutide. Valuation of on-label and off-label use of Pemvidutide across all indications and comorbidities show that Altimmune is significantly undervalued at current share prices, factoring in all risks. |
seekingalpha.com |
2024-12-16 05:14:23 |
Czytaj oryginał (ang.) |
| Altimmune CEO on what's next for its experimental obesity drug |
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, potential commercial partnership and more. |
youtube.com |
2024-12-03 20:04:04 |
Czytaj oryginał (ang.) |
| Altimmune Stock Up More Than 25% in a Month: Here's Why |
ALT's recent progress related to the development of the lead product candidate, pemvidutide, for treating obesity and MASH is aiding the stock. |
zacks.com |
2024-12-02 12:31:15 |
Czytaj oryginał (ang.) |